Evidence map›Paper›PMID 42410964›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

A Droplet-Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients' Blood Plasma Samples.

Yi Liu, Ruolin Zhang, Jialei Song, Meng Xiao, Yue Meng, Zhiyang Li, Jingyu Shi, Yunyan Tai, Bing Gu, Mo Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi LiuDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P. R. China.
Ruolin ZhangDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P. R. China.
Jialei SongDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P. R. China.
Meng XiaoLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
Yue MengLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
Zhiyang LiDepartment of Clinical Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, P. R. China.
Jingyu ShiDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P. R. China.
Yunyan TaiDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P. R. China.
Bing GuLaboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
Mo YangDepartment of Biomedical Engineering, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, P. R. China.ORCID 0000-0002-3863-8187

Funding

Guangdong-Hong Kong Technology Cooperation Funding Scheme GHP/032/20SZGuangdong-Hong Kong Technology Cooperation Funding Scheme SGDX20201103095404018Hong Kong Polytechnic University Internal Fund 1-CD8MHong Kong Polytechnic University Internal Fund 1-CDKUHong Kong Polytechnic University Internal Fund 1-CDQBHong Kong Polytechnic University Internal Fund 1-CDQRHong Kong Polytechnic University Internal Fund 1-CE2JHong Kong Polytechnic University Internal Fund 1-CEB1Hong Kong Polytechnic University Internal Fund 1-W02CHong Kong Polytechnic University Internal Fund 1-WZ4EHong Kong Polytechnic University Internal Fund 1-YWDUHong Kong Polytechnic University Internal Fund 4-TD45Hong Kong Research Grants Council (RGC) Collaborative Research Fund C5005-23 WHong Kong Research Grants Council (RGC) Collaborative Research Fund C5078-21EResearch Grants Council (RGC) Hong Kong General Research Fund 15216622Research Grants Council (RGC) Hong Kong General Research Fund 15217621Shenzhen Science and Technology Program-Basic Research Scheme JCYJ20220531090808020
6 · The paper itself

Abstract

Breast cancer is highly heterogeneous, with distinct subtypes-luminal A, HER2-positive, and triple-negative-each exhibiting unique behaviors and treatment responses. Accurate identification of these subtypes is essential for guiding personalized therapies and improving outcomes. Exosomes, small extracellular vesicles secreted by tumor cells, have emerged as critical biomarkers for cancer diagnostics due to their pivotal role in intercellular communication and their rich molecular cargo reflective of cell origin. However, current exosome-based biosensors struggle to differentiate between breast cancer subtypes, limiting their effectiveness in precision medicine. To address this challenge, we have developed an innovative droplet-microarray platform integrated with a DNase I-assisted MoS

Indexed as

Breast NeoplasmsExosomesBiomarkers, TumorFemaleHumansBiomarkers, Tumorbreast cancer subtypesexosomesFRETmultiplex detection

Identifiers

PMID42410964
PMCPMC13533275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.